ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2512

Golimumab Therapy Retention Rates in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthritis: Data from the Italian Lorhen Registry

Vittorio Grosso1, Roberto Gorla2, Piercarlo Sarzi-Puttini3, Fabiola Atzeni4, Raffaele Pellerito5, Enrico Fusaro6, Giuseppe Paolazzi7, Pier Andrea Rocchetta8, Ennio Giulio Favalli9, Antonio Marchesoni10 and Roberto Caporali11, 1Division of Rheumatology,, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, 2Reumatologia, Spedali Civili, Brescia, Italy, 3Rheumatology Unit, University Hospital L Sacco, Milan, Italy, 4Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, 5Rheumatology, Ospedale Mauriziano, Turin, Italy, 6Department of Rheumatology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, 7Rheumatology, Santa Chiara Hospital, Trento, Italy, 8Struttura di Reumatologia A.S.O. «SS.Antonio e Biagio e C.Arrigo», Alessandria, Italy, 9Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, 10Department of Rheumatology, Gaetano Pini Institute, Milano, Italy, 11Rheumatology, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), Biologic agents, psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Therapeutic Strategies, Biomarkers and Predictors of Outcomes in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Golimumab therapy retention rates in patients with rheumatoid arthritis and seronegative spondyloarthritis: data from the Italian LORHEN registry

Background/Purpose

The efficacy of Golimumab (GLM) treatment in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has been widely documented. In everyday clinical practice, however, many patients discontinue therapy due to adverse events (AE), lack of efficacy or other reasons. [1] We compared first year retention rates of GLM treatment among RA, PsA and AS, using the first one as reference standard, in a multicentric observational cohort (the LORHEN Registry).

Methods

All patients in the LORHEN database who started GLM were included. All patients were treated according to current EULAR recommendations for the management of RA and spondyloarthritis. Drug survival during the first year of treatment was measured, along with specific reasons  for discontinuation (inefficacy or adverse events). We compared drug retention rates using the Kaplan-Meier method. Cox regression analyses, using RA as reference category, were used to adjust for age, sex, disease duration, number of previous csDMARDs and treatment with low dose prednisone.

Results

134 RA patients, 84 PsA patients and 108 AS patients were included. 49 (37%) RA patients, 29 (35%) PsA patients and 22 (20%) AS patients discontinued treatment during the first year. Thirty-six (27%) and 12 (9%) RA patients, 17 (20%) and 11 (13%) PsA patients, 14 (13%) and 7 (6%) AS patients discontinued GLM due to lack of efficacy or AE, respectively.

Patients with a diagnosis of AS showed a lower, but not significant, risk of discontinuation, with an adjHR (95%CI) of 0.35 (0.10 – 1.17).

Patients treated with low dose prednisone showed a reduced risk of discontinuation with an adjHR (95%CI) of 0.35 (0.14 – 0.86). Age, sex, disease duration and number of previous csDMARDs did not significantly influence the risk of discontinuation.

Conclusion

AS patients seem to have better GLM retentions rates with respect to RA and PsA patients; however this difference is significantly reduced after adjusting for confounders.

The significantly lower adjHR observed for low dose prednisone therapy might reflect a beneficial effect even in patients treated with bDMARDs.

References

[1] Scirè CA et al. Clin Exp Rheumatol. 2013;31:857-63.

RA

PsA

AS

Total

Number of patients

134

84

108

326

Male (%)

24 (18%)

41 (49%)

60 (56%)

125 (38%)

Age (years), mean (±sd)

53,42 (±17,58)

48,10 (±13,29)

48,48 (±11,92)

49,42 (±15,19)

Disease duration (yrs), mean (±sd)

8,47 (±13,79)

10,68 (±17,17)

22,56 (±33,31)

13,71 (23,62)

Active smokers, num (%)

20 (15%)

13 (15%)

21 (19%)

54 (17%)

Previous csDMARDs, num (IQR)

2 (1 – 3)

2 (1 – 2)

1 (0 – 1)

2 (1 – 2)

Treatment with prednisone, num (%)

117 (87%)

71 (85%)

68 (63%)

256 (79%)

Table 1.Patients at baseline. IQR: interquartile range.

 


Disclosure:

V. Grosso,
None;

R. Gorla,
None;

P. Sarzi-Puttini,
None;

F. Atzeni,
None;

R. Pellerito,
None;

E. Fusaro,
None;

G. Paolazzi,
None;

P. A. Rocchetta,
None;

E. G. Favalli,
None;

A. Marchesoni,
None;

R. Caporali,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/golimumab-therapy-retention-rates-in-patients-with-rheumatoid-arthritis-and-seronegative-spondyloarthritis-data-from-the-italian-lorhen-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology